[Canpep*] Company's New Drug CBL-514 Injection for Abdominal Subcutaneous Fat Reduction, Second Pivotal Phase 3 Trial (CBL-0302) Clears US FDA IND 30-Day Review, Trial to be Initiated

AI Summary (NQ-processed)

Biotech firm Canpep Inc. announced that its second pivotal Phase 3 clinical trial (CBL-0302) for the novel drug CBL-514, targeting the reduction of abdominal subcutaneous fat, has passed the U.S. FDA's 30-day IND review period without comment. This approval allows the company to initiate the crucial late-stage trial, a significant milestone toward potential commercialization.